Oasmia Pharmaceutical AB (publ)

Interim report for the period May – July 2010

PHASE III STUDY WITH PACCAL® VET COMPLETED

THE QUARTER IN BRIEF May 1 2010 – July 31 2010

- Consolidated net sales amounted to TSEK 42 (24 657)[1]
- Operating income amounted to TSEK -11 216 (10 624)
- Net income after tax amounted to TSEK -12 090 (9 386)
- Earnings per share was SEK -0,32 (0,28)
- Comprehensive income amounted to TSEK -12 090 (9 386)
- The Phase III study with Paccal® Vet completed
- Oasmia signs a MSEK 75 SEDA agreement
- The Oasmia share is listed on NASDAQ OMX

EVENTS AFTER CLOSING DAY

- Oasmia appoints Carnegie Investment Bank AB as financial advisor
- New MSEK 40 credit facility
- An application for registration of Paccal® Vet has been submitted to EMA
- Clinical study shows good tolerance for Doxophos® Vet
- Oasmia revises financial goal after billion dollar deal in the business
- Two thirds of the patients are enrolled in the Phase III study with Paclical®
- The Phase III study with Paccal Vet submitted to FDA.

[1] The numbers in parentheses concerns results for the corresponding period previous year

KEY EVENTS DURING THE PERIOD

OASMIA HUMAN HEALTH

The international Phase III study on ovarian cancer commenced in February 2009 has continued in the period. The company's pharmaceutical candidate Paclical® is compared to the well-known pharmaceutical Taxol® in the study. The Study comprises about 80 clinics in 16 European countries and is expected to include 650 patients.

OASMIA ANIMAL HEALTH

In May, Oasmia reported preliminary results from the Phase III study with dogs diagnosed with mastocytoma (mast cell tumours), a type of skin cancer. In the study, it is investigated how dogs responded to treatment with Paccal® Vet compared to the pharmaceutical CCNU. The latter drug contains the active substance lomustine. CCNU is registered for human use, but is also used within veterinary health care. There is no registered veterinary pharmaceutical which contains the active substance paclitaxel, which Paccal Vet does. The preliminary results supported the presupposition that the clinical effect in dogs treated with Paccal Vet was significantly better compared to dogs treated with the alternative. In total, 249 dogs were included in the study and it comprised 26 clinics in seven European countries and the USA.

THE COMPANY

Oasmia signs MSEK 75 SEDA agreement

In July, the company signed a Standby Equity Distribution Agreement (SEDA agreement) with YA Global Master SPV Ltd (YA Global) which is controlled by USA based Yorkville Advisors LLC. According to the agreement, YA Global has committed to providing up to MSEK 75 in the upcoming 36 months, by subscription of newly issued Oasmia shares. Oasmia are fully entitled to decide for itself if and when the company chooses to utilize these rights for the entire term. The agreement provides Oasmia with a flexible access to further capital up to MSEK 75.

Listing on NASDAQ OMX

In June (June 24, 2010) the Oasmia share was listed on NASDAQ OMX. The share is listed in Stockholm among Swedish shares – Small Cap.

Oasmia appoints Remium as market maker

In June, Oasmia appointed Remium as market maker for the Oasmia share. The purpose is to reduce the difference between sales- and buy price and increase the liquidity of the share.

Björn Björnsson proposed as new Member of the Board

In May, the Oasmia nomination committee decided to propose Björn Björnsson as a new Member of the Board at the 2010 Annual General Meeting, held on September 28, 2010.

EVENTS AFTER CLOSING DAY

Oasmia appoints Carnegie Investment Bank AB as financial advisor

Oasmia has appointed Carnegie Investment Bank as financial advisor, in order to investigate the possibilities to raise liquid funds through new share issue or other financial instruments. The company will need additional liquid funds for the financing of further product development and to secure future production capacity.

New credit facility

The principal owner Oasmia S.A. has placed another credit facility at Oasmia Pharmaceutical AB's disposal. The facility amounts to MSEK 40, and the total credit now amounts to MSEK 100. The terms of the new credit are the same as for the previous credit facility of MSEK 60 provided by Oasmia S.A. in February. The interest is 6 %. The credit may be utilized by Oasmia at any time and is valid until August 2011 and automatically extended by 12 months if the credit is not cancelled by either party at the latest three months before the term expiration date.

The Phase III study with Paccal Vet submitted to EMA

In August an application for registration of Paccal Vet for treatment of mastocytoma in the EU was submitted to EMA.

Clinical study shows good tolerance for Doxophos® Vet
A Canadian study in dogs performed by Oasmia showed that proposed doses of Doxophos Vet were well tolerated. The study also showed a rapid distribution and no accumulation of active substance.

Oasmia revises financial goal after billion dollar business deal in the industry.
In August, the Oasmia Board of Directors decided to revise the financial goals after a billion dollar deal in the industry which has set a new and higher price level for the new generation of taxane drugs only comprised by Abraxane® and Paclical®. The Board decided that the company no longer should have any financial goals based on new license agreements. The Board estimates that the value of the innovations grows; the closer the products are to their markets.

Two thirds of the patients enrolled in the Phase III study with Paclical.
In August, two thirds of the patients were enrolled in the Phase III study with the product candidate Paclical. The total number of patients is estimated to 650.

The Phase III study with Paccal® Vet reported to FDA
In August, clinical data from the Phase III study with Paccal Vet was reported to FDA, as a part of the registration process for Paccal Vet in the USA.

FINACIAL PROSPECTS

The company aims to obtain a registration of Paccal Vet, its first product for the veterinary market, in the second half of 2010. License and distribution agreements have been closed for the main world markets, which enables Paccal Vet to be launched in 2011. The launch will enable Oasmia to receive milestone payments and royalties.

The company aims to obtain a registration of Paclical, its first product for human use, in the second half of 2011. The Board of Directors estimates that there are very good prospects for license agreements within Human Health.

The company previously had the goal to sign at least one new essential license and distribution agreement before the end of August 2010. The Board made the estimation that in the twelve-month period starting when such an agreement is signed, the net turnover would increase significantly and a positive operating income and cash flow would be reached as a result of closing further essential license and distribution agreements. The Board has decided that Oasmia no longer shall have any financial goals based on closing new license agreements, since it estimates the value of the innovations to grow, the closer the products are to their markets.

The Board has set the goal that the debt/equity ratio shall not exceed 50 %. It was 32 % at the end of the period.

The business activities are financed by equity, credits and licensing. Management continuously pays attention to these instruments to optimize the capital structure.

BUSINESS ACTIVITES

Oasmia develops a new generation of pharmaceuticals within human and veterinary oncology. The product development aims to manufacture novel formulations of well-established cytostatics which in comparison to current alternatives have improved properties, a reduced side-effect profile, and a wider therapeutic spectrum. The product development is based on in-house research within nanotechnology and company patents.

Oasmia's innovations can potentially be used within other areas, and therefore the company conducts some basic research within therapeutic areas such as infection, asthma and neurology.

Oasmia supervises the clinical trials with in-house personnel where several have an extensive international experience within clinical development and regulatory affairs. Manufacture of products for clinical trials is carried out in the company facilities in Uppsala.

FINANCAL INFORMATION

Consolidated Income Statement in brief

TSEK	2010 May-July	2009 May-July	2009/10 May-April
Net sales	42	24 657	30 741
Capitalized development cost	20 017	24 438	80 643
Operating income	-11 216	10 624	-14 961
Net income after tax	-12 090	9 386	-17 054
Earnings per share (SEK), before and after dilution	-0,32	0,28	-0,48
Comprehensive income for the period	-12 090	9 386	-17 054

Net sales
Net sales for the quarter amounted to TSEK 42 (24 657). Compared to the same period previous year, the company had no license revenues and no sales of parallel imported pharmaceuticals.

Capitalized development cost
Capitalized development cost consists of the company's investments in clinical Phase III trials. They amounted for the quarter to TSEK 20 017 (24 438). The reduction is the result of that the clinical study with Paccal Vet is completed.

Capitalized development costs per product candidate are displayed in note 3.

Operating expenses
The total operating expenses excluding depreciations and impairments amounted to TSEK 30 238 (37 596). The reduction is attributable to that the clinical study for Paccal Vet has been completed and that expenses related to parallel imported pharmaceuticals are zero.

Of the operating expenses, 66 % (65) were capitalized as Capitalized development costs.

The number of employees at the end of the quarter was 69 (56 as of July 31, 2009).

Net profit for the period
The net profit for the quarter was TSEK -12 090 (9 386). The difference in profit is attributable to that the first quarter previous year contained license revenues of TSEK 23 065.

The business activities of the Group have not been affected by seasonal variations or cyclic effects.

Financial position
The consolidated liquid assets at the end of the quarter amounted to TSEK 107 (15 247). Equity at the same time amounted to TSEK 129 713 (70 593). At the end of the quarter, the equity/assets ratio was 67 % (53) and the debt/equity ratio 32 % (34).

Cash flow and Capital expenditures
Cash flow from operating expenses in the quarter amounted to TSEK -9 076 (11 350). The change compared to the previous year consisted mainly of license revenues in the previous year.

Capital expenditures amounted to TSEK 22 884 (25 009) where investments in intangible assets amounted to TSEK 20 017 (24 668) and investments in property, plant and equipment amounted to TSEK 2 868 (341). Investments in intangible assets consisted of capitalized development costs. Investments in property, plant and equipment mainly concerned production equipment in the facility in Uppsala.

The financing were comprised of new loans and an increase in liabilities to credit institutions by TSEK 26 696 (14 457).

The parent company

The parent company net sales in the quarter amounted to TSEK 42 (23 157) and net income after tax amounted to TSEK -12 113 (9 737). The parent company liquid assets at the end of the quarter amounted to TSEK 32 (15 242).

Key ratios and other information

	2010 May-July	2009 May-July	2009/10 May-April
Number of shares at the close of the period (in thousands), before and after dilution*	37 613	33 735	37 613
Average number of shares (in thousands) before and after dilution*	37 613	33 735	35 800
Earnings per share in SEK, before and after dilution*	-0,32	0,28	-0,48
Equity per share, SEK*	3,45	2,09	3,77
Equity/Assets ratio, %	67	53	79
Net liability, TSEK	41 428	24 130	9 467
Debt/Equity ratio, %	32	34	7
Return on total assets, %	neg	10	neg
Return on equity, %	neg	14	neg
Number of employees at the end of the period	69	56	64

* Recalculation of historical values has been made with respect to capitalization issue elements in the preferential rights share issue carried out in the second quarter 2009.

Definitions

Earnings per share, before and after dilution: The income for the period attributable to the equity holders of the parent company divided by a weighted average number of shares, before and after dilution.
Equity per share: Equity in comparison with the number of shares at the end of the period
Equity/assets ratio: Equity pertaining to the balance sheet total.
Net liability: Total borrowing (containing the balance sheet items Short-term and Long-term borrowings and liabilities to credit institutions) with deductions for liquid funds
Debt/Equity ratio: Net liability with respect to equity.
Return on total equity: Income for interest expenses pertaining to the average balance sheet total.
Return on equity: Income after financial items in relation to the average equity.

Consolidated Income statement

TSEK	Note	2010 May-July	2009 May-July	2009/10 May-April
Net sales		42	24 657	30 741
Capitalized development cost		20 017	24 438	80 643
Other operating income		27	-	-
Raw materials, consumables and goods for resale		-2 662	-3 979	-18 842
Other external expenses		-18 133	-26 213	-74 412
Employee benefit expenses		-9 443	-7 404	-29 413
Depreciation/amortization and impairment		-1 064	-875	-3 612
Other operating expenses		-	-	-68
Operating income		**-11 216**	**10 624**	**-14 961**
Financial income		19	323	411
Financial expenses		-893	-1 561	-2 505
Financial items, net		**-874**	**-1 238**	**-2 094**
Income before taxes		**-12 090**	**9 386**	**-17 055**
Taxes	2	0	0	0
Income for the period		**-12 090**	**9 386**	**-17 054**
Income for the period attributable to:				
Equity holders of the Parent company		-12 089	9 393	-17 016
Minority shareholding		-1	-7	-38
Earnings per share				
Before dilution, SEK		-0,32	0,28	-0,48
After dilution, SEK		-0,32	0,28	-0,48

Consolidated Statement of Comprehensive income

TSEK	Note	2010 May-July	2009 May-July	2009/10 May-April
Income for the period		-12 090	9 386	-17 054
Comprehensive income for the period		**-12 090**	**9 386**	**-17 054**
Comprehensive income for the period attributable to:				
Equity holders of the Parent company		-12 089	9 393	-17 016
Minority shareholding		-1	-7	-38
Comprehensive Earnings per share				
Before dilution, SEK		-0,32	0,28	-0,48
After dilution, SEK		-0,32	0,28	-0,48

Consolidated statement of financial position

TSEK	Note	2010-07-31	2009-07-31	2010-04-30
ASSETS				
Non-current assets				
Property, plant and equipment		22 687	19 539	20 665
Capitalized development cost	3	160 877	84 654	140 860
Other intangible assets		7 829	7 877	8 047
Financial assets		2	2	2
Total Non-current assets		**191 395**	**112 072**	**169 574**
Current assets				
Inventories		94	1 465	94
Trade receivables		-	159	60
Other current receivables		1 326	1 714	2 090
Prepaid expenses and accrued income		1 211	1 608	2 460
Liquid assets		107	15 247	5 372
Total Current assets		**2 737**	**20 192**	**10 076**
TOTAL ASSETS		**194 132**	**132 264**	**179 650**
EQUITY				
Equity attributed to equity holders in the Parent Company				
Share capital		3 761	3 350	3 761
Other capital provided		196 493	99 254	196 493
Retained earnings		-70 597	-32 100	-58 509
Total		**129 657**	**70 504**	**141 746**
Minority shareholding		56	89	57
Total equity		**129 713**	**70 593**	**141 803**
LIABILITIES				
Non-current liabilities				
Other non-current liabilities		15 397	15 397	15 397
Deferred tax liabilities		7	7	7
Total Non-current liabilities		**15 404**	**15 404**	**15 404**
Current liabilities				
Liabilities to credit institutions		4 985	6 166	4 289
Short-term borrowings	4	36 550	33 211	10 550
Trade payables		612	1 313	2 076
Other current liabilities		1 449	1 235	1 197
Accrued expenses and prepaid income		5 419	4 341	4 332
Total Current liabilities		**49 015**	**46 267**	**22 443**
Total Liabilities		**64 419**	**61 671**	**37 847**
TOTAL EQUITY AND LIABILITIES		**194 132**	**132 264**	**179 650**
Contingent liabilities	5			
Pledged assets	5			

Consolidated statement of changes to shareholders' Equity

TSEK	Share capital	Other paid-up capital	Retained earnings	Minority sharehold-ing	Total sharehold-ers' equity
	Attributable to Equity holders in Parent company				
Opening balance as of May 1 2009	**3 350**	**99 254**	**-41 493**	**95**	**61 207**
Comprehensive income for the period	-	-	9 393	-7	9 386
Closing balance as of July 31 2009	**3 350**	**99 254**	**-32 100**	**89**	**70 593**
Opening balance as of May 1 2009	**3 350**	**99 254**	**-41 493**	**95**	**61 207**
Comprehensive income for the year	-	-	-17 016	-38	-17 054
New share issues	411	102 410	-	-	102 821
Issue expenses	-	-5 171	-	-	-5 171
Closing balance as of April 30 2010	**3 761**	**196 493**	**-58 509**	**57**	**141 803**
Opening balance as of May 1 2010	**3 761**	**196 493**	**-58 509**	**57**	**141 803**
Comprehensive income for the period	-	-	-12 089	-1	-12 090
Closing balance as of July 31, 2010	**3 761**	**196 493**	**-70 597**	**56**	**129 713**

Consolidated Cash flow statement

TSEK	Note	2010 May-July	2009 May-July	2009/10 May-April
Operating activities				
Operating income		-11 216	10 624	-14 961
Depreciation/amortization		1 064	875	3 612
Impairment of inventory		-	-	300
Disposals of intangible assets		-	-	68
Interest received		19	323	411
Interest paid		-893	-1 330	-2 178
Cash flow from operating activities before working capital changes		**-11 026**	**10 493**	**-12 748**
Change in working capital				
Change in inventories		-	1 312	2 383
Change in trade receivables		60	2 178	2 277
Change in other current receivables		2 013	-493	-1 722
Change in trade payables		-1 463	-1 712	-950
Change in other current liabilities		1 339	-427	-475
Cash flow from current operations		**-9 076**	**11 350**	**-11 235**
Investing activities				
Investments in intangible fixed assets		-20 017	-24 668	-81 773
Investments in property, plant and equipment		-2 868	-341	-3 541
Cash flow from investing activities		**-22 884**	**-25 009**	**-85 315**
Financing activities				
Increase in liabilities to credit institutions		696	-	-
Reduction in liabilities to credit institutions		-	-1 190	-3 067
Increase in non-current liabilities		-	15 373	15 373
New share issues		-	-	74 083
Issue expenses		-	-	-5 171
New loans	4	26 000	14 457	25 007
Amortization of loans		-	-722	-5 290
Cash flow from financing activities		**26 696**	**27 918**	**100 934**
Cash flow for the period		**-5 265**	**14 259**	**4 384**
Cash and cash equivalents at the beginning of the period		**5 372**	**988**	**988**
Cash and cash equivalents at the end of the period		**107**	**15 247**	**5 372**

Parent Company Income statement

TSEK	Note	2010 May-July	2009 May-July	2009/10 May-April
Net sales		42	23 157	28 817
Capitalized development cost		20 017	24 438	80 643
Other operating income		27	125	125
Raw materials, consumables and goods for resale		-2 633	-2 571	-15 869
Other external expenses		-18 081	-26 112	-74 051
Employee benefit expenses		-9 443	-7 404	-29 413
Depreciation/amortization and impairment of property, plant, equipment and intangible assets		-1 018	-818	-3 385
Operating income		**-11 089**	**10 814**	**-13 133**
Profit from participations in Group companies	6	-150	-150	-3 570
Other interest revenues and similar revenues		19	323	411
Interest cost and similar costs		-893	-1 250	-2 109
Financial items, net		**-1 024**	**-1 077**	**-5 268**
Income after financial items		**-12 113**	**9 737**	**-18 401**
Taxes	2	-	-	-
Income for the period		**-12 113**	**9 737**	**-18 401**

Parent Company Balance Sheet

TSEK	Note	2010-07-31	2009-07-31	2010-04-30
ASSETS				
Non-current assets				
Intangible fixed assets				
Capitalized development cost	3	160 877	84 654	140 860
Concessions, patents, licenses, trademarks and similar rights		7 458	7 223	7 630
Property, plant and equipment				
Equipment, tools, fixtures and fittings		22 687	19 539	20 665
Financial assets				
Participations in group companies		298	2 118	298
Receivables from group companies		4	4	4
Other securities held as non-current assets		1	1	1
Total Non-current assets		**191 324**	**113 539**	**169 458**
Current assets				
Inventories				
Raw materials and consumables		94	106	94
		94	106	94
Current receivables				
Trade receivables		-	-	60
Receivables from group companies	4	220	-	370
Other current receivables		1 318	1 807	2 019
Prepaid expenses and accrued income		1 131	1 487	2 332
		2 669	3 294	4 782
Cash and bank balances		32	15 242	5 320
Total current assets		**2 794**	**18 643**	**10 196**
TOTAL ASSETS		**194 118**	**132 182**	**179 653**
EQUITY AND LIABILITIES				
Equity				
Restricted equity				
Share capital		3 761	3 350	3 761
Statutory reserve		4 620	4 620	4 620
		8 381	7 970	8 381
Non-restricted equity				
Share premium reserve		196 493	99 254	196 493
Retained earnings		-63 030	-44 628	-44 628
Income for the period		-12 113	9 737	-18 401
		121 351	64 363	133 464
Total equity		**129 732**	**72 333**	**141 845**
Non-current liabilities				
Other non-current liabilities		15 373	15 373	15 373
Total non-current liabilities		**15 373**	**15 373**	**15 373**
Current liabilities				
Short term borrowings	4	36 550	33 211	10 550
Trade payables		611	626	2 068
Liabilities to Credit institutions		4 985	-	4 289
Liabilities to group companies	4	-	5 247	-
Other current liabilities		1 449	1 057	1 197
Accrued expenses and prepaid income		5 419	4 334	4 332
Total Current liabilities		**49 013**	**44 476**	**22 435**
TOTAL EQUITY AND LIABILITIES		**194 118**	**132 182**	**179 653**
Contingent liabilities and pledged assets				
Contingent liabilities	5	-	8 000	-
Pledged assets	5	5 000	-	5 000

Change in shareholders' equity Parent Company

TSEK	Restricted equity Share capital	Restricted equity Statutory reserve	Non-restricted equity	Total equity
Opening balance as of May 1 2009	**3 350**	**4 620**	**54 626**	**62 596**
Income for the period	-	-	9 737	9 737
Closing balance as of July 31 2009	**3 350**	**4 620**	**64 363**	**72 333**
Opening balance as of May 1 2009	**3 350**	**4 620**	**54 626**	**62 596**
New share issues	411	-	102 410	102 821
Issue expenses	-	-	-5 171	-5 171
Income for the period	-	-	-18 401	-18 401
Closing balance as of April 30 2010	**3 761**	**4 620**	**133 464**	**141 845**
Opening balance as of May 1 2010	**3 761**	**4 620**	**133 464**	**141 845**
Income for the period	-	-	-12 113	-12 113
Closing balance as of July 31 2010	**3 761**	**4 620**	**121 351**	**129 732**

Note 1 Accounting policies

This interim report is established in accordance with IAS 34, Interim Reporting and the Securities market Act. The consolidated accounts for the Oasmia group has been established in accordance with the International Financial Reporting Standards (IFRS) such as they have been adopted by the EU and interpretations of International Financial Reporting Interpretation Committee (IFRIC) RFR 1.3, Complementary accounting regulations for Groups and the Annual Accounts Act. The Parent Company accounts are established in accordance with RFR 2.3, Accounting for legal entities and the Annual Accounts Act. The Group and Parent company accounting policies and calculation methods are unchanged compared to the ones described in the Annual Report for the fiscal year May 1 2009 – April 30 2010. The new and revised accounting standards applied by Oasmia as of May 1 2010 have not had any effect on the Oasmia financial statements.

Note 2 Taxes

The Group has accumulated losses carried forward amounting to TSEK 109 061 (70 620) of which the Parent Company has TSEK 100 276 (63 684). Of the total losses carried forward for the Group, TSEK 17 881 (17 881) are restricted for use through group contributions. This limitation will end by the 2014 tax assessment. The future tax effect of these losses carried forward has not been marked with a value and no deferred tax asset has been considered in the Balance Sheet.

Note 3 Capitalized development cost

TSEK	2010-07-31	2009-07-31	2010-04-30
Paclical®	91 409	36 645	76 227
Paccal® Vet	69 468	48 009	64 633
Total	160 877	84 654	140 860

Note 4 Transactions with related parties

Essential transactions with related parties are disclosed below.

The principal owner Oasmia S.A has in the period provided Oasmia with a credit facility amounting to MSEK 60. The contract credit is valid until March 2011 and is automatically renewed with 12 months if the credit is not cancelled by either part 3 months before the term expiry date at the latest. The contract interest is 6 %. The unused credit at July 31, 2010 amounted to TSEK 36 550 (as of July 31 2009, the company had raised loans from Oasmia S.A amounting to TSEK 31 000). Oasmia's claim in the subsidiary Qdoxx Pharma AB amounted as of July 31, 2010 to TSEK 220 (liability as of July 31, 2009 amounted to TSEK 5 247). Oasmia has in the period made a group contribution to Qdoxx Pharma AB of TSEK 150 (150). See also note 5.

Note 5 Contingent liabilities and Pledged assets

The company holds a TSEK 5 000 bank overdraft, with a floating charge of corresponding amount as security.

Note 6 Participations in group companies

Impairments of participations in the wholly owned subsidiary Qdoxx Pharma AB has been made, corresponding to maid group contributions amounting to TSEK 150 (150) as the reason was to cover losses in the subsidiary. The impairments are accounted for in the Parent company income statement in the item Participations in group companies.

Note 7 Risk factors

The Group is subjected to a number of different risks through its business. By creating awareness of the risks involved in the activities these risks can be limited, controlled and managed and at the same time as business opportunities can be utilized to increase earnings. The risks to Oasmia's business activities are described in the Annual report for the fiscal year May 1 2009 – April 30 2010. No additional risks beyond those described therein have been judged significant.

The Board of Directors and CEO of Oasmia Pharmaceutical AB ensures that this Interim report gives a correct overview of the Parent Company and Group activities, position and result and describes essential risks and uncertainty factors that the Parent Company and the companies that are part of the Group faces.

Uppsala, September 9, 2010

Bo Cederstrand, Chairman

Claes Piehl, Member

Peter Ström, Member

Julian Aleksov, Member and Chief Executive Officer

The information in this Interim report is such that Oasmia Pharmaceutical (publ) must publish according to the code of trade in financial instruments. The information was delivered for publication on September 9, 2010 at 09.00.

This interim report has not been reviewed by the company auditors.

COMPANY INFORMATION

Oasmia Pharmaceutical AB (publ)
VAT-number: SE556332-667601
Seat: Stockholm

Address and telephone number to the Main Office
Vallongatan 1
752 28 UPPSALA, SWEDEN
+46 18 50 54 40
www.oasmia.com
info@oasmia.com

Questions concerning the report are answered by:
Julian Aleksov, CEO
+46 18 50 54 40

UPCOMING REPORT DATES

Interim Report May – October 2010	2010-12-09
Interim Report May 2010 – January 2011	2011-03-10
Year-end Report May 2010 – April 2011	2011-06-10
Annual Report May 2010 – April 2011	2011-08-25
Interim report May – July 2011	2011-09-08